This medication is used in situations involving certain distressing symptoms where the clinical context includes both retained secretions and allergic manifestations. The therapeutic approach for the mucolytic component is consistent with established practice for managing respiratory secretions.

This medication is commonly used to help with conditions like acute or chronic bronchitis, and allergic rhinitis. It is relevant when supportive symptom management is appropriate for difficult phlegm expulsion and concurrent allergic irritation.

“It may help patients cope more steadily with symptom fluctuations by addressing the dual discomfort of thick mucus and allergic irritation.”

Symptom Management Focus

The medication helps address symptom clusters that may become intense or disruptive, specifically viscid, excessive phlegm leading to productive cough, alongside allergic manifestations such as sneezing, runny nose, and nasal pruritus. By actively assisting in the loosening and thinning of secretions, it contributes to easing the overall symptom load related to congestion, while the anti-allergic action is relevant for easing symptoms related to inflammatory or irritative states. This assists with maintaining functional stability during symptomatic phases.

Quick Fact: Relief for Dual Discomfort
Primary Focus	Viscid Secretions and Allergic Irritation
Symptom Goal	Easing overall symptom load and promoting comfort
Use Context	Conditions involving heightened symptoms and mucus retention

Eligibility Map: Who Can and Cannot Use Пульмолор — Official Regulatory Information

Eligibility Scope

Classification	Population or Condition
Use Allowed	Adults; Children ge 6 years (tablets) or ge 2 years (liquid forms).
Not Recommended	Children under 2 years of age; Pregnant or Lactating individuals.
Contraindicated	Documented Hypersensitivity to active ingredients; Acute Porphyria; Severe Hepatic Impairment.

Age-related eligibility rules:

Official labels restrict the medicine to populations 2 years of age and older. Use in older adults is generally permitted, though some regulatory documents advise caution due to potential increased sensitivity.

Condition-specific eligibility rules:

Use requires caution in patients with non-severe renal impairment or hepatic impairment, as well as those with a history of stomach ulcer or seizure disorders, as explicitly noted in official regulatory documentation.

---

Connection to the overall eligibility profile

Official regulatory documents define the eligible population for Пульмолор by establishing three primary categories: absolute prohibitions (contraindications) for severe conditions or known allergies; age-based and physiological exclusions for young children and reproductive health states; and conditional use warnings for patients with specific comorbidities or organ function challenges. This structure explicitly delineates the populations authorized for use from those restricted or prohibited, strictly according to label-based criteria.

The official interaction profile for Пульмолор focuses on the pharmacokinetic changes involving the Loratadine component and the pharmacodynamic or distribution effects of the Ambroxol component, strictly based on regulatory documentation.

Pharmacokinetic Interactions (Exposure Modification)

The Loratadine component is metabolized via the CYP3A4 and CYP2D6 enzymes and is subject to interactions that substantially increase its systemic exposure. Co-administration with known inhibitors of these enzymes, specifically Ketoconazole, Erythromycin, and Cimetidine, results in a notable increase in the plasma concentrations of Loratadine and its active metabolite.

Interacting Substance	Official Outcome	Classification
CYP3A4/2D6 Inhibitors	Substantially increased Loratadine exposure	Pharmacokinetic
Food	Increased Loratadine bioavailability (~40% increase in AUC)	Physiological Absorption

Pharmacodynamic and Distribution Effects

Interactions involving the Ambroxol component include restrictions related to its secretolytic action. Co-administration with cough suppressants (antitussives) is subject to a restriction due to the potential for airway obstruction caused by the retention of thinned secretions.

Official documentation notes that concurrent use of Ambroxol with antibiotics, including Amoxicillin, Cefuroxime, and Erythromycin, leads to higher concentrations of the antibiotic in bronchial secretions and sputum.

Population-Specific Notes

Regulatory labeling advises that patients with hepatic or renal impairment may experience reduced clearance of Loratadine and its metabolites, increasing the potential for drug accumulation when co-administered with medicines that affect clearance.

Mucus Viscosity and Secretion Modulation

This domain covers the action of Ambroxol as a secretagogue and mucolytic agent. It targets specific cells in the airway lining to stimulate the production of less viscous fluid and pulmonary surfactant, while simultaneously depolymerizing thick mucus fibers. This mechanism enhances the rate of mucociliary transport and facilitates the expulsion of retained bronchial secretions.

---

Peripheral Histamine Receptor Antagonism

This mechanistic domain is governed by Loratadine, which acts as a selective inverse agonist/antagonist at the peripheral Histamine H1 receptors ( H1 R). By occupying and stabilizing these receptors, it blocks the binding of the inflammatory mediator histamine, thereby halting the signaling cascade responsible for vascular leakage and sensory nerve stimulation. This results in a decrease in the signaling and manifestation of histamine-mediated peripheral responses.

---

Dual-Mechanism Airway Modulation

The mechanism involves the co-action of two distinct components, engaging two independent physiological control systems. This dual modulation concurrently influences the rheological state of secretions (lower airways) and the histamine-mediated responses (upper airways). The combined action results in the concurrent modulation of the mucociliary and peripheral allergic pathways.

Administration Principles and Official Regimens

Пульмолор (Ambroxol and Loratadine) is a fixed-dose combination medication designated strictly for the oral route of administration, available as Tablets and Oral Liquid (syrup) formulations. The general usage pattern is determined by the long-acting nature of the antihistamine component and is typically scheduled for administration once daily or twice daily.

Dosing Instructions and Frequency

The standard adult regimen usually involves a single or multiple doses totaling 10 mg of the Loratadine component per day, which is the established dose for this ingredient. The accompanying Ambroxol dosage is administered according to the specific fixed combination strength. The medication can generally be taken without regard to mealtime. However, tablets must be swallowed whole, and the liquid formulation requires measurement using a dedicated dosing device to ensure accurate volume delivery.

Usage Duration and Specific Population Rules

Treatment is intended for short-term symptomatic use only. Continued use beyond a brief acute phase often requires re-evaluation of the condition, as prolonged administration is not the standard protocol. Specific adjustments for vulnerable populations include:

• Severe Hepatic Impairment: For patients with severe liver dysfunction, an extension of the dosing interval for the Loratadine component is necessary. An example of a recommended adjustment is 10 mg every other day.
• Severe Renal Impairment: Dose modification or extension of the dosing interval may be required, particularly for the Ambroxol component, in cases of severe renal disease.
• Children: Dosing is often weight- or age-based, with the Oral Liquid form used for younger children to facilitate precise dosing.

Evidence for Use in Allergic Rhinitis Associated with Cough

Research has focused on the combination product, and studies examined symptom patterns in conditions involving both allergic manifestations and cough. The clinical investigation conducted for this combination included short-term, randomized controlled trials (RCTs). These trials observed patient-reported outcomes and evaluated symptom changes over the defined study period.

These trials primarily included populations of school-aged children—specifically, those between 6 and 12 years of age who were experiencing co-existing cough and symptoms of allergic rhinitis. Research examined outcomes related to physical discomfort, and studies monitored patient-reported outcomes describing perceived discomfort, such as sneezing, nasal congestion, and the severity and pattern of cough. Research describes patterns observed in the studies over typically short time intervals, relating how symptoms were reported in the observed populations.

---

Long-Term Studies and Follow-up

Existing clinical evidence is primarily focused on research exploring short-term symptom changes for conditions where symptoms may vary in intensity. The follow-up durations used in the primary clinical trials were short, usually extending to only about ten days of observation. Therefore, long-term effects are not fully established for the combination product. Research has not yet defined the long-term patterns or durability of the observed responses, and there is limited information for long-term outcomes in conditions characterized by fluctuating or episodic manifestations.

---

Evidence in Special Populations

The published clinical trials relevant to co-existing allergic rhinitis and cough largely focused on a defined pediatric population (children aged 6 to 12 years). This means that results apply only to the populations studied, and data for other groups remain insufficient. While other types of research, such as analytical and pharmacokinetic studies, have involved healthy adult volunteers to evaluate drug concentration profiles, widespread clinical evidence derived from large-scale trials in the general adult population remains insufficient.

---

What is Still Uncertain About Пульмолор

Evidence derived from settings with varying symptom burdens is limited in scope. The sample sizes were modest in the studies conducted, meaning the findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

The evidence base currently has limited comparative evidence, such as comprehensive systematic reviews or meta-analyses, which would combine findings from multiple sources. Consequently, certainty remains low when generalizing the findings to populations experiencing more complex or chronic respiratory disorders beyond the scope of the original short-term trials. These factors highlight what is known—and what is still uncertain—regarding the available research.

Key Studies & References Effect over ten days of treatment with the combination loratadine/ambroxol in pediatric solution, on the clinical allergic rhinitis symptoms associated to cough, in a 6-12 years old pediatric patients

Common questions about Пульмолор (FAQ)

Q: Does Пульмолор help with a wet cough or a dry cough?

A: The official mechanism of action is designed for coughs associated with mucus. The Ambroxol component is classified as a mucolytic agent, meaning its primary role is to thin and break down thick, excessive bronchial secretions. This action is consistent with how the drug addresses symptoms of a wet or productive cough. Additionally, the Loratadine component addresses allergic symptoms that can cause cough and irritation.

Q: How long does the effect of one dose of Пульмолор typically last?

A: Official product information notes the long-acting nature of the Loratadine component, indicating a duration of effect that supports the prescribed interval. The medicine is typically scheduled for administration once daily or twice daily.

Q: Can people with liver problems use Пульмолор?

A: Official regulatory documents state that use requires caution in patients with non-severe hepatic impairment. Severe hepatic impairment is listed as a contraindication, which generally prohibits the use of the drug. For patients with severe hepatic impairment, regulatory documents note that specific adjustments to the dosing interval may be described.

Q: Are there any special considerations for using Пульмолор if I have diabetes?

A: The official product documentation lists 'increased appetite' as a common adverse reaction for the drug. While the drug label does not impose specific restrictions related to diabetes, patients managing their weight or glucose levels may need to consider this common side effect.

Q: What kind of research evidence is available to support the use of Пульмолор?

A: Research supporting the drug has focused on short-term, randomized controlled trials (RCTs). These studies examined patient-reported outcomes related to cough and allergic symptoms. The trials primarily included populations of school-aged children experiencing co-existing cough and allergic rhinitis symptoms.

Q: What information is available about the safety profile of Пульмолор?

A: The safety profile is based on the official regulatory documentation for its two active components, Ambroxol and Loratadine. This profile classifies adverse reactions by frequency. It also details warnings regarding rare but serious adverse reactions like Anaphylactic Reactions and Severe Cutaneous Adverse Reactions (SCARs).

Q: How is Пульмолор different from other cough or cold medicines I can buy?

A: This drug is a fixed-dose combination containing two distinct active ingredients to address different symptoms simultaneously. It includes a mucolytic agent (Ambroxol), which works to thin mucus, and a long-acting, second-generation antihistamine (Loratadine), which blocks the body's allergic responses.

Q: Can I use Пульмолор for symptoms other than what is listed on the package?

A: Official regulatory documents define the drug's purpose for specific, approved indications, such as relief from phlegm-associated cough and allergic symptoms. Use outside of these indications is not supported by the product labeling.

Q: How quickly should I expect to feel an effect after taking Пульмолор?

A: Information based on the Loratadine component suggests that initial effects may typically be observed within the first few hours after administration. The drug is designed for symptomatic relief.

Q: Are there any common supplements or vitamins that interact with Пульмолор?

A: Official sources note that there is limited information on the specific interaction between the Loratadine component and common supplements or herbal remedies. Caution is typically advised for supplements that may cause side effects like sleepiness or a dry mouth, as these effects might be additive.

Q: Is it safe to use Пульмолор with non-prescription pain relievers like paracetamol or ibuprofen?

A: Official advice regarding the Loratadine component notes that interactions are generally not expected when taken with non-prescription pain relievers such as paracetamol or ibuprofen.

Q: Can Пульмолор be used by children, and if so, what is the approved age range?

A: Official labels generally restrict the use of the medicine to populations 2 years of age and older. The oral liquid form is typically specified for children ge 2 years, while the tablet form is indicated for older children ge 6 years of age.

Q: Is there a known risk of dependence or addiction with Пульмолор?

A: The active ingredients are classified as a mucolytic agent and a second-generation antihistamine. Regulatory labeling does not include warnings or scheduling related to controlled substance properties, which are associated with risks of dependence or addiction.

Q: What is the approved use of Пульмолор in patients with mild asthma?

A: Official regulatory documents define the drug's purpose as combined relief for conditions characterized by excessive, thick phlegm and coexisting allergic manifestations. The approved indication is not expanded to include the treatment of asthma as a primary condition.

Q: What is the difference between the capsule form and the tablet form of Пульмолор?

A: Official regulatory documentation lists the available forms as Tablets and Oral Liquid (syrup) formulations. The capsule form is not listed in the official regulatory documentation as an available formulation.

Q: Is it safe to drink alcohol while taking Пульмолор, according to official sources?

A: Official sources note that alcohol may increase the potential for drowsiness when taking the Loratadine component. Regulatory labeling suggests caution regarding concurrent use.

Q: Is it normal to feel a change in mucus consistency after starting Пульмолор?

A: Yes, a change in mucus is expected due to the drug's mechanism. The Ambroxol component is a mucolytic agent that works to thin and break down thick mucus fibers. This action should result in the expulsion of thinned secretions.

Q: Does Пульмолор contain any common allergens like gluten or lactose?

A: Regulatory labels for the Loratadine component in some tablet formulations list Lactose Monohydrate as an inactive ingredient. Official labels often note if the product is certified to be gluten-free.

Q: Is there a maximum number of days a person should use Пульмолор?

A: Official documents state that treatment is intended for short-term symptomatic use only, as prolonged administration is not the standard protocol described in the label.

Q: Can I use Пульмолор if I have a cough related to smoking?

A: The drug is intended for relief from phlegm-associated cough and coexisting allergic manifestations. The regulatory label does not restrict its use based on the cause of the cough, but its action is specific to addressing thick mucus that needs to be cleared.

Q: Are there any specific driving or operating machinery restrictions mentioned for Пульмолор?

A: Because somnolence (drowsiness) is listed as a common adverse reaction, official sources indicate that caution is necessary when performing tasks that require mental alertness, such as driving or operating machinery.

Q: Is it true that Пульмолор can be used for ear and sinus problems?

A: The approved purpose is for relief from phlegm-associated cough and allergic symptoms. While the antihistamine component may help with some upper respiratory tract symptoms, the approved indications do not list ear infections or sinusitis as explicit uses for this drug.

Q: Are there any dietary restrictions specifically mentioned when taking Пульмолор?

A: Official documentation notes a physiological interaction where taking the drug with food may increase the Loratadine component's bioavailability. No other major dietary restrictions (beyond alcohol) are specifically addressed in regulatory documents.

Q: Why is it important to check for drug interactions with over-the-counter medicines?

A: Official documentation for the drug notes that co-administration with certain over-the-counter medicines, such as cough suppressants, is subject to a restriction due to the potential for airway obstruction from the retention of thinned secretions.

Q: Can I take Пульмолор if I have a fever along with my cough?

A: The approved indication is for cough and allergic symptoms. Official labeling lists fever as an uncommon side effect, but the presence of fever is not listed as a contraindication to the use of the drug.

Q: Does the time of day I take Пульмолор matter for its effectiveness?

A: The medicine is typically scheduled for administration once daily or twice daily due to the long-acting component. Adherence to the scheduled interval is the primary factor, which may be determined by a healthcare provider.

Q: How is the safety of the drug monitored after it is made available to the public?

A: Governmental drug agencies, such as the FDA, perform Post-Marketing Surveillance (PMS) to continuously monitor the quality, safety, and efficacy of drug products once they are available to the public. This process collects and assesses new information on adverse events.

Storage and Disposal of Пульмолор

The storage of Пульмолор (Ambroxol and Loratadine combination) must strictly follow the conditions specified in the official regulatory labeling to ensure product quality. The medicine must be kept in its original container and protected from excessive moisture.

Required storage temperature ranges are typically between 20 C and 25 C for tablets, or not exceeding 30 C for oral liquid formulations. It is a mandatory requirement that this medicine be stored out of the sight and reach of children.

Disposal must adhere to local, regional, and national regulations. Unused or expired product should not be disposed of in household waste or wastewater, as regulatory documents specify that the product should not be released into the environment.